Did anyone notice that the AACR presentation summary slide only referred to only overall survival (OS) benefit and not for progression-free survival (PFS)? Any thoughts?
I'm aware that OS is the primary endpoint and not PFS for the Her-Vaxx study. However, the AACR presentation indicated that there was a benefit to both OS and PFS based on the survival curves. I'm just curious as to why both aren't mentioned in the investor webinar slide.
Ann: Investor Presentation, page-50
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(2.04%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $424.8K | 8.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 8622849 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1925890 | 9 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |